Author: OurCrowd

[Cybersixgill in Accesswire] Cybersixgill partners with Nisos to deliver Threat Intelligence-as-a-Service to help solidify companies’ proactive security posture

Aug 3, 2023 |

TEL AVIV, ISRAEL and ARLINGTON, VA / ACCESSWIRE / August 3, 2023 / Cybersixgill, the global cyber threat intelligence data provider, announced today its strategic partnership with Nisos, a leader in Managed IntelligenceTM, to bridge the gap between intelligence and action through a combined managed threat intelligence service. Through this partnership, Cybersixgill and Nisos enable customers to operationalize Cybersixgill’s market-leading cyber threat intelligence (CTI) with Nisos’ Managed Intelligence Monitoring service.  Read more...

Read More

[Arrow Global in Funds Europe] Exploring new opportunities: Private credit in European financing

Aug 3, 2023 |

In a global financial landscape marked by tightening regulatory conditions, the real prospects of recession, and the continued retreat of traditional banks, private credit has carved a niche for itself, particularly in Europe. Here, small and medium enterprises (SMEs), professional real estate developers and the corporate credit sector are finding private credit firms a reliable alternative to conventional banking systems. As banks retrench, they leave behind a critical lending need filled by private credit entities. Read...

Read More

[Quai.MD in No Camels] AI platform helps diagnose chest pain swiftly and accurately

Aug 3, 2023 |

Chest pain is a common problem with dozens of causes that range from harmless bruised muscles from coughing to potentially fatal pulmonary embolisms. But for the person involved, the experience can be a frightening one – even when the cause turns out to be relatively minor. Now an Israeli startup has developed an AI-based platform to help doctors diagnose patients with chest issues, accurately and in real time. Read more...

Read More

[Colossal in Forbes] Biotech companies are ripe for machine learning adoption

Aug 3, 2023 |

We are at the infancy of the biotech industry’s adoption of machine learning tools. But, over the next 20 years, a more “multidisciplinary and data-intensive approach to life sciences will shift our understanding of and ability to manipulate living matter.” However, lack of data sophistication is limiting the potential for rapid advancement right now. And, in my opinion, the more we wait, the more we will fall behind. Read more...

Read More